Sotagliflozin effect on HbA1c, weight may vary by kidney function, dose

Key takeaways:

Sotagliflozin improved HbA1c and body weight for patients with type 2 diabetes.

The treatment effect varied by kidney function; patients with worse kidney function had diminished benefit vs. placebo.

ORLANDO — In patients with type 2 diabetes, sotagliflozin improved HbA1c and body weight compared with placebo, though the treatment effect varied by kidney function, according to a meta-analysis.

In addition, among patients with impaired kidney function, sotagliflozin (Inpefa, Lexicon) 400 mg performed better vs. placebo than sotagliflozin 200 mg, according to the researchers.

Sotagliflozin 400 mg provides greater improvements in HbA1c and body weight than then 200 mg dose for adults with impaired kidney function. Image: Adobe Stock

Belinda Hardin, PharmD, senior direct